Pingchuan Pharmaceutical

Pingchuan Pharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to developing innovative small molecule drugs for cancer and autoimmune diseases. The company's research focuses on the DNA damage response (DDR) pathway and protein homeostasis. Its lead program, PC-002, is a potent and selective USP1 inhibitor currently undergoing Phase 1/2 clinical evaluation for advanced solid tumors, particularly those with homologous recombination deficiency (HRD). Pingchuan aims to deliver first-in-class therapies by leveraging its deep expertise in medicinal chemistry and cancer biology. The company is backed by prominent venture capital firms and operates a state-of-the-art R&D facility in the Suzhou Industrial Park.